Choose Language
Select a language for news translation.
At Holdings Channel , we have reviewed the latest batch of the 57 most recent 13F filings for the 06/30/2026 reporting period, and noticed that Eli Lilly (Symb…
Written by Sara Appino for The Motley Fool -> Abbott Laboratories maintains a diversified business model spanning diagnostics, medical devices, and nutrition …
Written by Prosper Junior Bakiny for The Motley Fool -> Expanding the GLP-1 market with new launches and label expansions will help Eli Lilly overcome increas…
Dow Jones Futures: Market Rebounds, Now Watch For This; SpaceX, AMD, Sandisk, Eli Lilly Earnings Loom
Written by Matthew Benjamin for The Motley Fool -> Both companies are giants in diabetes and obesity treatments. Lately, Eli Lilly has moved ahead in the obe…
Written by Prosper Junior Bakiny for The Motley Fool -> Revolution Medicines has a promising cancer drug in development. Even with this medicine's prospects,…
Vanguard’s VHT offers lower fees and double the dividend yield of Invesco’s IBBQ through broader healthcare exposure. This makes VHT a cost-effective choice fo…
The VanEck Pharmaceutical ETF (PPH) targets 25 pharmaceutical companies, while the State Street Health Care Select Sector SPDR ETF (XLV) includes 60 positions …
Novo Nordisk A/S (NYSE: NVO ) was at the center of media coverage as it sued rival weight loss drug manufacturer Eli Lilly on Tuesday. The firm claimed that Li…
